State Court Activity
Active in California state court (Hardiman, Harris estates); Jolly class action filed San Francisco Superior Court Case No. CGC-24-621022
Pharmaceutical · drug-safety monitoring around Oxbryta and possible litigation tied to adverse events or market actions
Defendant
Pfizer Inc.
MDL / Track
See litigation status
N.D. Cal.
Judge
Judge Trina L. Thompson
Plaintiffs
18 pending
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Pfizer voluntarily withdrew Oxbryta (voxelotor) from global markets in September 2024 after confirmatory trials and real-world registry studies showed higher rates of vaso-occlusive crises and death in treated patients. Federal litigation is proceeding in the Northern District of California, where three cases—Frazier v. Global Blood Therapeutics, Jolly v. Global Blood Therapeutics, and Allen v. Global Blood Therapeutics—have been coordinated before a single judge with a jury trial scheduled for June 7, 2027 in the Allen matter. Plaintiffs allege Pfizer and Global Blood Therapeutics failed to warn of serious risks including vaso-occlusive crises, stroke, organ failure, and death despite knowing or having reason to know of safety signals from clinical development data and post-market surveillance.
Causation Theory
Oxbryta's mechanism as a hemoglobin S polymerization inhibitor, while increasing hemoglobin levels, appears to disrupt tissue oxygenation and blood flow dynamics in ways that promote vaso-occlusive crises rather than prevent them. Post-marketing clinical trials demonstrated higher rates of vaso-occlusive crises and fatal events in voxelotor-treated patients compared to placebo, findings corroborated by two real-world registry studies. A 2025 retrospective FAERS database analysis by Lin et al. identified disproportionate reporting signals for sickle cell anemia with crisis (ROR 3782.72), acute chest syndrome (ROR 709.84), and sickle cell disease exacerbation (ROR 675.08) relative to hydroxyurea controls.
Litigation status
No MDL exists. Multiple individual cases pending in N.D. Cal. under Judge Trina L. Thompson, who issued coordination orders consolidating three federal actions (Frazier, Jolly, Allen). First trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). Class certification briefing set for June 2026 in Jolly. Settlement mediation ongoing with extensions granted.
State Court Activity
Active in California state court (Hardiman, Harris estates); Jolly class action filed San Francisco Superior Court Case No. CGC-24-621022
Geographic exposure
Approximately 100,000 sickle cell disease patients in U.S., 90% non-Hispanic Black or African American; pediatric approval expanded 2021 to ages 4-11, creating substantial exposed population with potential latency to September 2024 withdrawal date.
Federal coordination order issued May 2025 consolidating three cases: Frazier v. Global Blood Therapeutics, Inc., Jolly et al. v. Global Blood Therapeutics, Inc., and related actions before single judge — earliest bellwether trial set June 7, 2027 in Tirrell Allen v. Pfizer Inc. et al., N.D. Cal.
Plaintiff Tirrell Allen (resident of Illinois) filed federal suit November 2024 alleging stroke and severe vaso-occlusive crises after August 2024 Oxbryta initiation — case selected as first federal trial.
Multiple wrongful death and personal injury actions filed December 2024-January 2025 including estate of Marissa Harris; state court filing by Trebor Hardiman October 2024 alleging stroke with permanent vision loss; California widow filed April 2025 malpractice/Oxbryta design defect suit.
236 children aged 2-15 with high stroke risk enrolled across several countries — 8 deaths in Oxbryta arm vs. 2 in placebo arm reported 2024.
88 patients aged 12+ with known Oxbryta exposure — 8 deaths reported prompting safety signal.
Key defendants
Pfizer Inc.
Role: Manufacturer
Aggressive preemption defense in personal injury and consumer class actions. Motion to dismiss pending in Allen (3:24-cv-07786-TLT) and Jolly (3:24-cv-09345-TLT), both set for hearing July 8, 2025 before Judge Trina L. Thompson. Argues FDA labeling authority bars state law claims; no 'newly acquired information' for CBE label change. Trial date set for June 7, 2027 in lead personal injury case.
Global Blood Therapeutics, Inc.
Role: Manufacturer
Co-defendant with Pfizer in all pending actions. Acquired by Pfizer in 2022; original developer of Oxbryta. Joint defense posture on preemption and standing. No indemnity disputes visible in case management statements.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Pfizer Inc. | Manufacturer | Aggressive preemption defense in personal injury and consumer class actions. Motion to dismiss pending in Allen (3:24-cv-07786-TLT) and Jolly (3:24-cv-09345-TLT), both set for hearing July 8, 2025 before Judge Trina L. Thompson. Argues FDA labeling authority bars state law claims; no 'newly acquired information' for CBE label change. Trial date set for June 7, 2027 in lead personal injury case. |
| Global Blood Therapeutics, Inc. | Manufacturer | Co-defendant with Pfizer in all pending actions. Acquired by Pfizer in 2022; original developer of Oxbryta. Joint defense posture on preemption and standing. No indemnity disputes visible in case management statements. |
Timeline
FDA Grants Accelerated Approval
FDA grants accelerated approval to Oxbryta (voxelotor) for sickle cell disease in adults and pediatric patients aged 12 and older based on HOPE trial surrogate endpoint data. FDA grants fast track and orphan drug designations.
FDA Expands Approval to Ages 4-11
FDA grants accelerated approval for Oxbryta in children aged 4-11 years based on HOPE-KIDS 1 phase 2a study data. Approval includes new 300mg dispersible tablet formulation.
European Commission Grants Marketing Authorization
European Commission grants marketing authorization for Oxbryta for hemolytic anemia due to sickle cell disease in patients 12 years and older, following EMA PRIME designation and orphan medicinal product status.
Pfizer Announces Global Voluntary Withdrawal
Pfizer voluntarily withdraws all lots of Oxbryta from worldwide markets and discontinues all clinical trials. Decision based on post-marketing data showing imbalance in vaso-occlusive crises and fatal events. EMA CHMP had initiated review in July 2024.
First Oxbryta Lawsuit Filed
Plaintiff Trebor Hardiman files first Oxbryta lawsuit in state court alleging drug caused increased vaso-occlusive crises, swelling, and significant pain.
Defendants File Motion to Dismiss in Jolly Class Action
Global Blood Therapeutics and Pfizer file Motion to Dismiss in Ricky Jolly et al. v. Global Blood Therapeutics, Inc. et al., N.D. Cal., asserting federal preemption of state law claims.
N.D. Cal. Orders Coordination of Federal Cases
U.S. District Court for the Northern District of California issues order coordinating three federal Oxbryta actions—Frazier, Jolly, and Allen—under single judge. Case management conference scheduled for July 10, 2025.
Judge Thompson Sets First Trial Date for September 2027
Judge Trina L. Thompson sets September 13, 2027 trial date in Diana Ford v. Global Blood Therapeutics, Inc. et al., N.D. Cal. Case involves wrongful death of Bruce Ford following stroke after increased VOCs on Oxbryta.
Settlement Talks Scheduled with Mediator
Parties schedule potential settlement talks with mediator. No MDL established; cases remain in individual state and federal courts with coordinated management in N.D. Cal.
Statute of limitations
No MDL established as of March 2026; federal cases coordinated in N.D. Cal. under Judge Trina L. Thompson. September 26, 2024 FDA alert and Pfizer global withdrawal is the critical discovery date for most plaintiffs. Intake priority: Tennessee (1-year SOL expiring September 2025 for pre-withdrawal injuries).
California
2 years from injury
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause
First trial date set: Allen v. Global Blood Therapeutics, Inc., N.D. Cal., Judge Trina L. Thompson, trial June 7, 2027; Ford v. Global Blood Therapeutics, trial Sept. 13, 2027. Federal cases coordinated May 2025 under single judge in N.D. Cal. No MDL yet. September 2024 withdrawal likely triggers discovery rule for many plaintiffs.
Illinois
2 years from discovery of injury
Rule: 735 ILCS 5/13-202; discovery rule per Witherell v. Weimer, 421 N.E.2d 869 (Ill. 1981)
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its causal connection to defendant's conduct
Active filings reported; Tirrell Allen (Illinois resident) filed November 2024. September 2024 global withdrawal is likely discovery date for most plaintiffs.
⚠Tennessee
1 year from discovery of injury
Rule: Tenn. Code Ann. § 28-3-105; discovery rule per Shadrick v. Coker, 963 S.W.2d 726 (Tenn. 1998)
Discovery: Accrues when injury is discovered or reasonably should have been discovered; narrow construction—mere suspicion insufficient
Shortest SOL in major filing states. September 2024 withdrawal = hard discovery date. Intake must screen for any earlier symptoms that could trigger earlier accrual.
New York
3 years from discovery
Rule: N.Y. C.P.L.R. § 214-c; discovery rule per LaRosa v. Scientific Design Co., 402 N.E.2d 1275 (N.Y. 1980)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause; 10-year repose cap from act/omission per § 214-c(2)
2019 FDA approval to 2024 withdrawal falls within repose period. September 2024 withdrawal is clear discovery trigger.
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule per Neagle v. Nelson, 685 S.W.2d 11 (Tex. 1985)
Discovery: Accrues when plaintiff discovers, or in exercise of reasonable diligence should have discovered, the nature of the injury
Large sickle cell patient population. September 2024 withdrawal is discovery date for most. No MDL means state court filings likely.
Georgia
2 years from discovery
Rule: O.C.G.A. § 9-3-33; discovery rule per Am. Medical Int'l, Inc. v. Giurintano, 596 S.E.2d 604 (Ga. 2004)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, both the injury and its cause; 10-year repose for medical products per § 9-3-71(b)
Significant sickle cell population. 2019 approval to 2024 withdrawal within repose. September 2024 withdrawal = discovery trigger.
North Carolina
3 years from discovery
Rule: N.C. Gen. Stat. § 1-52(16); discovery rule per Sawyer v. Foster, 615 S.E.2d 42 (N.C. 2005)
Discovery: Accrues when plaintiff discovers, or should have discovered through reasonable diligence, the injury and its cause; 10-year repose per § 1-50(a)(5) for products liability
Extended SOL favorable for intake. September 2024 withdrawal is discovery date. Repose period covers 2019-2024 marketing.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| California | 2 years from injury | Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause | First trial date set: Allen v. Global Blood Therapeutics, Inc., N.D. Cal., Judge Trina L. Thompson, trial June 7, 2027; Ford v. Global Blood Therapeutics, trial Sept. 13, 2027. Federal cases coordinated May 2025 under single judge in N.D. Cal. No MDL yet. September 2024 withdrawal likely triggers discovery rule for many plaintiffs. |
| Illinois | 2 years from discovery of injury | 735 ILCS 5/13-202; discovery rule per Witherell v. Weimer, 421 N.E.2d 869 (Ill. 1981) | Accrues when plaintiff knows or reasonably should know of injury and its causal connection to defendant's conduct | Active filings reported; Tirrell Allen (Illinois resident) filed November 2024. September 2024 global withdrawal is likely discovery date for most plaintiffs. |
| ⚠Tennessee | 1 year from discovery of injury | Tenn. Code Ann. § 28-3-105; discovery rule per Shadrick v. Coker, 963 S.W.2d 726 (Tenn. 1998) | Accrues when injury is discovered or reasonably should have been discovered; narrow construction—mere suspicion insufficient | Shortest SOL in major filing states. September 2024 withdrawal = hard discovery date. Intake must screen for any earlier symptoms that could trigger earlier accrual. |
| New York | 3 years from discovery | N.Y. C.P.L.R. § 214-c; discovery rule per LaRosa v. Scientific Design Co., 402 N.E.2d 1275 (N.Y. 1980) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause; 10-year repose cap from act/omission per § 214-c(2) | 2019 FDA approval to 2024 withdrawal falls within repose period. September 2024 withdrawal is clear discovery trigger. |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule per Neagle v. Nelson, 685 S.W.2d 11 (Tex. 1985) | Accrues when plaintiff discovers, or in exercise of reasonable diligence should have discovered, the nature of the injury | Large sickle cell patient population. September 2024 withdrawal is discovery date for most. No MDL means state court filings likely. |
| Georgia | 2 years from discovery | O.C.G.A. § 9-3-33; discovery rule per Am. Medical Int'l, Inc. v. Giurintano, 596 S.E.2d 604 (Ga. 2004) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, both the injury and its cause; 10-year repose for medical products per § 9-3-71(b) | Significant sickle cell population. 2019 approval to 2024 withdrawal within repose. September 2024 withdrawal = discovery trigger. |
| North Carolina | 3 years from discovery | N.C. Gen. Stat. § 1-52(16); discovery rule per Sawyer v. Foster, 615 S.E.2d 42 (N.C. 2005) | Accrues when plaintiff discovers, or should have discovered through reasonable diligence, the injury and its cause; 10-year repose per § 1-50(a)(5) for products liability | Extended SOL favorable for intake. September 2024 withdrawal is discovery date. Repose period covers 2019-2024 marketing. |
Live intelligence
AI litigation brief
Oxbryta remains emerging with 17 current signals in the accepted feed.
Overview
No MDL exists. Multiple individual cases pending in N.D. Cal. under Judge Trina L. Thompson, who issued coordination orders consolidating three federal actions (Frazier, Jolly, Allen). First trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). Class certification briefing set for June 2026 in Jolly. Settlement mediation ongoing with extensions granted.
Key developments
Trajectory
Press and regulatory signals are moving in tandem for Oxbryta. The next escalation check is whether these agency actions prompt new PACER filings or MDL scheduling orders.
Editorial intelligence
Editorial coverage should stay tied to source-backed developments and avoid placeholder status copy for Oxbryta.
Generated Apr 28, 2026, 12:00 AM UTC
17 events detected
Google News (2)
NAACP and Singleton Schreiber Announce Official Partnership to Pursue Justice for Sickle Cell Patients Harmed by Pfizer’s Oxbryta - NAACP
NAACP and Singleton Schreiber Announce Official Partnership to Pursue Justice for Sickle Cell Patients Harmed by Pfizer’s Oxbryta - NAACP
Expert opinion on investigational drugs • Unguru Y • PMID 42007797 • Journal Article.
American journal of hematology • Power-Hays A • PMID 41830507 • Journal Article.
Blood advances • Xu M • PMID 41701977 • Journal Article.
Cells • Kanter J • PMID 41744769 • Journal Article.
Advanced healthcare materials • Rabiee N • PMID 41612602 • Journal Article.
No recent court filing signals. Monitoring is active — this section updates automatically.
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
42Score
Fresh items are present but not yet surging
Monitoring
Live
monitoring
Last: Apr 28, 2026, 12:00 AM UTC
Next: 46:02
Source Monitoring
PACER
PACER
Google News
FDA
PubMed
Event feed
17
events detected
AI Brief
Oxbryta remains emerging with 17 current signals in the accepted feed.
Overview
No MDL exists. Multiple individual cases pending in N.D. Cal. under Judge Trina L. Thompson, who issued coordination orders consolidating three federal actions (Frazier, Jolly, Allen). First trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). Class certification briefing set for June 2026 in Jolly. Settlement mediation ongoing with extensions granted.
Key developments
NAACP news on Sep 2: NAACP and Singleton Schreiber Announce Official Partnership to Pursue Justice for Sickle Cell Patients Harmed by Pfizer’s Oxbryta - NAACP. ‖ FAERS FDA alert on Dec 3: FAERS Filing 26118061: Death. ‖ PubMed research on Apr 23: Discontinued therapies for sickle cell disease: status and future directions..
Generated Apr 28, 2026, 12:00 AM UTC